MNKD vs. ANAB, PAHC, RDUS, VNDA, OMER, MDGL, ALKS, FOLD, MYGN, and CLDX
Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include AnaptysBio (ANAB), Phibro Animal Health (PAHC), Radius Recycling (RDUS), Vanda Pharmaceuticals (VNDA), Omeros (OMER), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Amicus Therapeutics (FOLD), Myriad Genetics (MYGN), and Celldex Therapeutics (CLDX).
AnaptysBio (NASDAQ:ANAB) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
MannKind received 221 more outperform votes than AnaptysBio when rated by MarketBeat users. However, 65.74% of users gave AnaptysBio an outperform vote while only 59.92% of users gave MannKind an outperform vote.
49.6% of MannKind shares are held by institutional investors. 33.7% of AnaptysBio shares are held by insiders. Comparatively, 3.0% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
MannKind has a net margin of 3.78% compared to MannKind's net margin of -711.17%. AnaptysBio's return on equity of -3.35% beat MannKind's return on equity.
AnaptysBio currently has a consensus price target of $51.89, suggesting a potential upside of 40.13%. MannKind has a consensus price target of $8.00, suggesting a potential upside of 38.65%. Given MannKind's higher possible upside, analysts plainly believe AnaptysBio is more favorable than MannKind.
In the previous week, AnaptysBio had 17 more articles in the media than MannKind. MarketBeat recorded 20 mentions for AnaptysBio and 3 mentions for MannKind. AnaptysBio's average media sentiment score of 1.03 beat MannKind's score of 0.60 indicating that MannKind is being referred to more favorably in the news media.
AnaptysBio has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
MannKind has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
Summary
MannKind beats AnaptysBio on 12 of the 18 factors compared between the two stocks.
Get MannKind News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MannKind Competitors List
Related Companies and Tools
